| Ytd | 52.68% | |
| 1y | 86.63% |
| Open | 14.42 | Prev Close | 14.30 | Low | 14.19 | High | 14.67 | Mkt Cap | 583.54M |
| Vol | 80.93K | Avg Vol | 120.50K | EPS | 0.23 | P/E | 63.13 | Forward P/E | 91.50 |
| Beta | 0.37 | Short Ratio | 0.33 | Inst. Own | 19.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 15.20 | 200-d Avg | 13.10 | 1yr Est | 13.72 |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy a
Brainsway (NASDAQ: BWAY - Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF - Get Free Repo
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. Whil
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflec
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report) has earned a consensus recommendation
Ladenburg Thalmann analyst Jeffrey Cohen maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 r
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
BrainsWay (NASDAQ:BWAY) raises FY2026 sales outlook from $66.000 million-$68.000 million to $68.000
BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.07 per share which missed the analyst cons
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for inte
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report)'s share price hit a new 52-week high d
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally s
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation
BrainsWay continues to actively evaluate similar investments in leading North American mental health
BTIG analyst Sam Eiber initiates coverage on BrainsWay (NASDAQ:BWAY) with a Buy rating and announ
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health pr
BWAY, HTLD and NCNO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14th, 202
HTLD, MEOH, NCNO, JD and BWAY have been added to the Zacks Rank #1 (Strong Buy) List on July 14th, 2
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BW
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental healt
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatm
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy a
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
Investment in provider servicing clinics in Illinois is latest in series of similar transactions by
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript
BrainsWay (NASDAQ:BWAY) affirms FY2026 sales outlook from $66.000 million-$68.000 million to $66.000
BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.06 per share which beat the analyst consen
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings an
Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings an
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global le
Top analysts change outlook on top names. HC Wainwright cut BWAY price target, Mizuho raised PENN ta
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy a
BrainsWay Ltd.
BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.04 per share which met the analyst consens
Health care sector has oversold stocks, RSI momentum indicator can help traders predict short term p